MediciNova (NASDAQ:MNOV) has announced clinical findings published in Cancer Chemotherapy and Pharmacology, related to MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN).
14 patients completed two cycles of chemotherapy, including one cycle with conventional chemotherapy and one of chemotherapy with concurrent MN-166 treatment.
Across all neurotoxicity measures, majority of participants either improved or showed no worsening of neurotoxicity with MN-166 treatment.
According to Oxaliplatin-Specific Neurotoxicity Scale, 12 out of 14 participants reported mild/moderate acute neurotoxicity in both cycles. Of those, 10 out of 12 participants were unchanged and 2 participants had improved symptoms from moderate to mild with MN-166 co-treatment.
It was also reported that co-administration of MN-166 (ibudilast) with oxaliplatin resulted in improvement or stabilization of oxaliplatin-induced neurotoxicity in the majority of participants treated with oxaliplatin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.